|Source||Humanized (from mouse)|
Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease.
PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons. Nevertheless, clinical trials continue for various diseases like multiple myeloma and diabetes mellitus type 1 as of July 2009[update].
- "PDL BioPharma, Development Pipeline - Nuvion (visilizumab)". Archived from the original on 2007-09-15. Retrieved 2008-02-11.
- "PDL Lands in a Hazard". Retrieved 2009-05-27.
- Clinical trial number NCT00938626 for "Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma" at ClinicalTrials.gov
- Kaufman A, Herold KC (May 2009). "Anti-CD3 mAbs for treatment of type 1 diabetes". Diabetes/Metabolism Research and Reviews. 25 (4): 302–6. doi:10.1002/dmrr.933. PMID 19319985. S2CID 36595661.
- Clinical trial number NCT00378508 for "Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes" at ClinicalTrials.gov
- Malviya G, D'Alessandria C, Bonanno E, Vexler V, Massari R, Trotta C, et al. (October 2009). "Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes" (PDF). Journal of Nuclear Medicine. 50 (10): 1683–91. doi:10.2967/jnumed.108.059485. PMID 19759100. S2CID 31980716.